Dimopoulos, Meletios A. http://orcid.org/0000-0001-8990-3254
Schjesvold, Fredrik http://orcid.org/0000-0003-1096-0569
Doronin, Vadim
Vinogradova, Olga http://orcid.org/0000-0002-3669-0141
Quach, Hang
Leleu, Xavier http://orcid.org/0000-0002-9822-4170
Montes, Yolanda Gonzalez
Ramasamy, Karthik
Pompa, Alessandra
Levin, Mark-David http://orcid.org/0000-0003-2139-3547
Lee, Cindy
Mellqvist, Ulf Henrik
Fenk, Roland
Demarquette, Hélène
Sati, Hamdi
Vorog, Alexander
Labotka, Richard
Du, Jichang
Darif, Mohamed
Kumar, Shaji http://orcid.org/0000-0001-5392-9284
Funding for this research was provided by:
Millennium Pharmaceuticals, Inc., Cambridge, MA, USA, a wholly owned subsidiary of Takeda Pharmaceutical Company Limited
Article History
Received: 25 June 2021
Revised: 18 November 2021
Accepted: 23 November 2021
First Online: 24 January 2022
Competing interests
: MAD reports receiving honoraria from Amgen, Takeda, BMS, Janssen, and Beigene. FS reports receiving honoraria from Amgen, Takeda, and Sanofi; consulting/advisory roles for Celgene, Janssen, Oncopeptides, and Sanofi; and research funding from Celgene, Sanofi, Janssen, Oncopeptides, and GSK. VD reports receiving honoraria from Takeda, Sanofi, and Janssen; consulting/advisory roles for Celgene, Janssen, and Sanofi; and research funding from Celgene, Sanofi, Janssen, Agios Pharmaceuticals Inc, and Pfizer. OV reports receiving honoraria from Takeda, Sanofi, Janssen, and BMS; consulting/advisory roles for Celgene, Janssen, Sanofi, and BMS; and research funding from Celgene, Janssen, Sanofi, and BMS. HQ reports consulting/advisory roles for and receiving honoraria from GSK, Sanofi, Janssen Cilag, BMS, Celgene, CSL, Amgen, Takeda, Karyopharm, and Antengene; and research funding from GSK, Amgen, Celgene, Sanofi, and Karyopharm. XL reports receiving honoraria from Janssen, Takeda, Sanofi, Bas, Novartis, Amgen, Oncopeptide, Karyopharm, Incyte, and GSK. YGM reports no conflicts of interest. KR reports consulting/advisory roles for Celgene/BMS, Takeda, Janssen, Amgen, AbbVie, Sanofi, Oncopeptides, Karyopharm, GSK, Adaptive Biotech, and Pfizer; has served on speakers bureaus for Celgene/BMS, and Takeda; has received research funding from Celgene/BMS, Takeda, Janssen, and Amgen; and travel, accommodation and expenses from Celgene/BMS, Takeda, and Janssen. AP has received honoraria and travel, accommodation and expenses from Janssen, Celgene, Takeda, and Amgen. M-DL reports consulting/advisory roles for and receipt of travel, accommodation, and expenses from Takeda, AbbVie, Janssen, Roche, and Amgen. CL reports a consulting/advisory role for Janssen and research funding from BMS. UHM reports receiving honoraria from BMS, Janssen, Sandoz, Takeda, Amgen, and Sanofi; and consulting/advisory roles for Amgen and Oncopeptides. RF reports consulting/advisory roles for and has received honoraria and travel, accommodation, and expenses from BMS/Celgene, GSK, Amgen, and Janssen. HD reports a consulting/advisory role for Novartis, and has received honoraria from Amgen and Novartis, and travel expenses from Janssen. HS has received honoraria from Takeda, Novartis, and Janssen; research funding from Celgene; and travel, accommodation and expenses from Celgene and Takeda. AV, RL, JD and MD are employees of Takeda. SK reports consulting/advisory roles (with no personal payment) for AbbVie, Amgen, BMS, Janssen, Roche-Genentech, Takeda, KITE, and Astra-Zeneca; consulting/advisory roles (with personal payment) for Oncopeptides, Beigene, and Antagene; and has received institutional research funding from AbbVie, Amgen, BMS, Carsgen, Janssen, KITE, Merck, Astra-Zeneca, Novartis, Roche-Genentech, Takeda, and Tenebio.